Country: New Zealand
Language: English
Source: Medsafe (Medicines Safety Authority)
Levobunolol hydrochloride 0.25%{relative}; ; ;
Allergan New Zealand Ltd
Levobunolol hydrochloride 0.25% w/v
0.25 %
Eye drops, solution
Active: Levobunolol hydrochloride 0.25%{relative} Excipient: Benzalkonium chloride Dibasic sodium phosphate heptahydrate Disodium edetate Hydrochloric acid Monobasic potassium phosphate Polyvinyl alcohol Purified water Sodium chloride Sodium hydroxide Sodium metabisulfite
Bottle, dropper, 1x5mL, 5 mL
Prescription
Prescription
Piramal Enterprises Limited
Package - Contents - Shelf Life: Bottle, dropper, - 5 mL - 24 months from date of manufacture stored at or below 25°C protect from light 4 weeks opened stored at or below 25°C protect from light
1990-07-03
BETAGAN ® 5% levobunolol hydrochloride Datasheet Version 3.0 DATA SHEET 1. PRODUCT NAME BETAGAN ® 5mg/mL eye drops 2. QUALITATIVE AND QUANTITATIVE COMPOSITION levobunolol hydrochloride 5mg/mL For full list of excipients, see section 6.1 List of Excipients. 3. PHARMACEUTICAL FORM Clear, colourless to slightly yellow, sterile ophthalmic solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Control of intraocular pressure in patients with open angle glaucoma. Control of ocular hypertension. Treatment of acute increased intraocular pressure following laser capsulotomy and extra-capsular cataract extraction. 4.2 DOSAGE AND METHOD OF ADMINISTRATION The recommended dose is one drop of BETAGAN ® 0.5% eye drops in the affected eye(s) twice a day. Studies have also shown that IOP is controlled in many patients with one drop of BETAGAN ® 0.5% eye drops in the affected eye(s) once a day. Careful monitoring of patients is advised, particularly in the first few days after starting treatment or if the dose of BETAGAN ® eye drops is increased. Dosages above one drop of BETAGAN ® 0.5% eye drops twice daily are not generally more effective. If the patient's IOP is not at a satisfactory level on this regimen, concomitant therapy with dipivefrine and/or adrenaline, and/or pilocarpine and other miotics, and/or systemically administered carbonic anhydrase inhibitors, such as acetozolamide, can be instituted. In order to minimise systemic absorption of BETAGAN ® eye drops, apply pressure to the tear duct immediately following administration of the drug._ _ PAEDIATRIC POPULATION Safety and effectiveness in children have not been established. 4.3 CONTRAINDICATIONS BETAGAN ® eye drops are contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma or severe chronic obstructive pulmonary disease (see 4.4 Special Warnings and Precautions for use); sinus bradycardia; sick sinus syndrome (including sino-atrial nodal block); second or third degree atrioventricular block not controlled with a Read the complete document